Last updated on May 2019

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Endogenous depression | Major depression | Tobacco abuse
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion criteria:

  1. adult (18 years of age or older) daily cigarette smokers (1+ cigarettes per day)
  2. meet criteria for current or lifetime MDD without psychotic features
  3. have or are willing to acquire a personal email address and access to a camera phone or other method for submission of therapy practice assignments
  4. speak, read, and write fluently in English
  5. able to provide written informed consent
  6. intend to reside in the geographic area for >8 months
  7. women of childbearing potential must agree to use a medically acceptable method of birth control or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends.

Exclusion criteria:

  1. current enrollment or plan to enroll in another smoking cessation program in the next 8 months
  2. regular (daily) use of e-cigarettes, chewing tobacco, snuff, snus, or other tobacco products
  3. current use or plan to use nicotine replacement therapy or other smoking cessation medication within the next 8 months
  4. medications indicated for bipolar or psychotic disorder if prescribed for bipolar or psychotic disorder
  5. pregnant or planning to become pregnant within the next 8 months, or breast feeding
  6. history of seizures or current seizure disorder without medication
  7. history of severe (stage IV or V) chronic kidney disease including current or prior end stage renal disease on either hemodialysis or peritoneal dialysis or prior renal transplant
  8. any prior solid organ transplant or prior hematopoietic stem cell transplant
  9. alcohol consumption exceeding 28 drinks per week
  10. cirrhosis or end-stage liver disease
  11. systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg after two readings or symptomatic uncontrolled stage II hypertension
  12. unstable cardiovascular disease within 3 months prior to baseline or other cardiovascular disease requiring hospitalization
  13. prior hospitalization for heart failure
  14. previous allergic reaction to varenicline
  15. high suicide risk based on the Columbia Suicide Severity Rating Scale
  16. lifetime bipolar or psychotic disorder as determined by either self-report or clinical interview

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.